News Details

The National Comprehensive Cancer Network Announces Promotions

JENKINTOWN, PA, February 23, 2004 – The National Comprehensive Cancer Network (NCCN), an alliance of 19 of the world`s leading cancer centers, is pleased to announce the promotion of two of its top executives, Alana L. K. Brody and Joan S. McClure.

Ms. Brody has been named Vice President, Business Development. In this position, she will lead NCCN`s relationships with the pharmaceutical and biotechnology industries, as well as oversee NCCN`s expansion of educational symposia and all related marketing initiatives. Ms. Brody has over a decade of healthcare experience. Prior to joining the NCCN, she helped to build the infrastructure of the National Spine Network (NSN), a national centers of excellence network of orthopaedic and neurosurgeons. She began her healthcare tenure as a marketing manager for Baystate Health Systems in Western Massachusetts. Ms. Brody holds an MBA from Rensselaer Polytechnic Institute and a BS from Syracuse University.

Ms. McClure has been named Vice President, Clinical Information and Publications. As such, she will direct the continuing development and extension of the NCCN Clinical Practice Guidelines in Oncology; NCCN/ACS Guidelines for Patients; and the Journal of the National Comprehensive Cancer Network; as well as the derivation of the forthcoming NCCN Drug, Biologics, and Diagnostic Compendia. Prior to joining the NCCN, Ms. McClure managed programs in oncology physician and patient information and in health data standardization in the public and private sectors. She received her BS and MS degrees from the University of Maryland, College Park.

The NCCN is fortunate to have the leadership of Ms. Brody and Ms. McClure to help shape the organization’s expansion, said William T. McGivney, PhD, Chief Executive Officer of NCCN. NCCN is in a dynamic growth phase as we have more than doubled our informational programs based on the NCCN Clinical Practice Guidelines during the past 18 months. NCCN guidelines continue to be the standard for clinical policy in oncology. NCCN continues to expand its influence in the oncology arena.